Biotech stocks are at the mercy of market-moving catalysts, and Cantor Fitzgerald analyst Louise Chen outlined potential outlined potential stock-moving events for eight biotech names in a Monday report. Mylan: Pipeline Update, Patent Challenge Mylan N.V. MYL 0.54% is scheduled to hold its investor day in New York City on April 11. The company is expected to shed light on the following: A recently announced biosimilar Botox program with Revance Therapeutics Inc RVNC 0.73%.A Humira biosimilar program.Its platform and pipeline. A U.S. Patent Trial and Appeal Board oral hearing for Allergan plc Ordinary Shares AGN 1.69%'s Restasis is scheduled for April 3. The PTAB denied St. Regis Mohawk Tribe's motion to terminate Mylan'sRestasis challenge over six Restasis-related patents, according to a Feb. 26 release from Mylan. A final decision on the challenged patents is scheduled for June 6. SourceWeak upside still holds. $MYL, Mylan N.V. / D